Hyattsville, Maryland Clinical Trials

A listing of Hyattsville, Maryland clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 291 clinical trials
Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection

This is a Phase II, randomized, observer-blind, placebo-controlled, multi-site trial of the FDA licensed rMenB+OMV NZ vaccine, Bexsero. The targeted study population is men and women 18-50 years of age who are disproportionately vulnerable to N. gonorrhoeae infection. Approximately 2,200 participants are expected to be enrolled to achieve at least …

Walter Reed National Military Medical Center
 (9.6 away) Contact site
  • 0 views
  • 13 Jun, 2021
  • +6 other locations
Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack

The purpose of this study is to try to find the best dose of the new drug BAY 2433334 to give to participants and to look at how well BAY 2433334 works on top of a dual antiplatelet therapy (acetylsalicylic acid +/- clopidogrel) in patients following a recent heart attack …

ck-mb
aspirin
clot
troponin
antiplatelet therapy
White Oak Medical Center
 (7.4 away) Contact site
  • 57 views
  • 09 Jun, 2021
  • +192 other locations
KEYMAKER-U01 Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-na ve Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) PLUS chemotherapy in combination with vibostolimab (MK-7684) or MK-5890 in treatment-nave participants with advanced squamous or non-squamous NSCLC. This study is one of three pembrolizumab substudies being conducted under one pembrolizumab umbrella master protocol (MK-3475-U01/KEYMAKER-U01).

pembrolizumab
paclitaxel
pemetrexed
carboplatin
carboplatin/paclitaxel
Georgetown University ( Site 0036)
 (7.8 away) Contact site
  • 2 views
  • 26 Apr, 2021
  • +24 other locations
A Study of TAK-994 in Adults With Narcolepsy

Adults with narcolepsy who have completed the TAK-994-1501 study will be able to take part in this study. The main aim of this study is to check if participants have side effects from TAK-994. Participants will take one of 3 different TAK-994 dose for 8 weeks. Then, half the participants …

Helene A. Emsellem, MD PC trading as "The Center for Sleep & Wake Disorders",150119420
 (7.8 away) Contact site
  • 0 views
  • 01 Jun, 2021
  • +137 other locations
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)

Rheumatoid Arthritis (RA) is an inflammatory disease of the joints causing pain, stiffness, swelling and loss of joint function. This study evaluates how safe and effective ABBV-154 is in participants treated for moderately to severely active RA. Adverse events and change in the disease activity will be assessed. ABBV-154 is …

stiffness
antirheumatics
rheumatism
methotrexate
The Center for Rheumatology and Bone Research /ID# 228617
 (8.6 away) Contact site
  • 0 views
  • 13 Jun, 2021
  • +255 other locations
KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-na ve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC ) (MK-3475-01B/KEYMAKER-U01B)

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) in combination with MK-4830 in treatment-nave participants with advanced squamous or non-squamous NSCLC that is PD-L1 positive. This study is one of three pembrolizumab substudies being conducted under one pembrolizumab umbrella master protocol (MK-3475-U01/KEYMAKER-U01).

Georgetown University ( Site 0036)
 (7.8 away) Contact site
  • 0 views
  • 01 May, 2021
  • +24 other locations
Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants

The purpose of this Phase 2a study is to establish safety and preliminary efficacy of treatment with danicamtiv in patients with primary dilated cardiomyopathy (DCM) due to MYH7 or TTN variants .

MedStar Georgetown University Hospital
 (7.9 away) Contact site
  • 0 views
  • 16 May, 2021
  • +17 other locations
Study of the Safety and Efficacy of AMT-101 in Subjects With Pouchitis

Phase 2 Study Investigating the Efficacy of AMT-101 in Subjects with Chronic Antibiotic-resistant Pouchitis

Chevy Chase Clinical Research
 (8.1 away) Contact site
  • 0 views
  • 13 Jun, 2021
  • +20 other locations
Treatment of Hemochromatosis

This study will evaluate the effectiveness of a test called MCV in guiding phlebotomy (blood drawing) therapy in patients with hemochromatosis an inherited disorder that causes too much iron to be absorbed by the intestine. The excess damages body tissues, most severely in the liver, heart, pancreas and joints. Because …

National Institutes of Health Clinical Center, 9000 Rockville Pike
 (9.7 away) Contact site
  • 4 views
  • 31 May, 2021
  • 1 location
Comparison of Non-Surgical Treatment Options for Chronic Exertional Compartment Syndrome (CECS)

Chronic Exertional Compartment Syndrome (CECS) in the lower leg is a debilitating condition in highly active individuals. Pain occurs in 1 or several leg compartments upon an exertional activity, typically running, that quickly dissipates once the activity stopped. Surgical fasciotomy is the standard for treating lower leg CECS, but success …

Walter Reed National Military Medical Center
 (9.6 away) Contact site
  • 0 views
  • 03 Apr, 2021
  • +1 other locations